Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now? [Yahoo! Finance]
Immunome, Inc. (IMNM)
Company Research
Source: Yahoo! Finance
Stock market data showing an upward trajectory. Photo by Burak The Weekender on Pexels The returns have been driven primarily by bullish outlooks on the stock's potential to treat desmoid tumors. On December 15, Immunome, Inc. (NASDAQ:IMNM) shared positive topline results from the Phase 3 RINGSIDE trial, demonstrating an improved survival rate without progression, when compared with a placebo. The results showed the drug decreased the likelihood of death or disease progression by 84%. According to the company's press release, 156 patients were part of the trial, of which about 56% of them had their tumors disappear or shrink in size, in contrast with 9% on placebo. Based on the results, Immunome, Inc. (NASDAQ:IMNM) said it plans on seeking approval from the FDA for Varegacestat in the second quarter of 2026. Following the results, Guggenheim, on December 22, revised its price target on the stock to $35 from $25, while keeping a Buy rating on the shares. The research firm expe
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome (IMNM) Is Up 11.7% After Phase 3 Varegacestat Success - Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
- Assessing Immunome (IMNM) Valuation After Recent Share Price Momentum And Conflicting P/B And DCF Signals [Yahoo! Finance]Yahoo! Finance
- Immunome (NASDAQ:IMNM) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $31.00 price target on the stock.MarketBeat
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Jim Cramer on Immunome: “If You Want to Speculate on It, Fine” [Yahoo! Finance]Yahoo! Finance
IMNM
Earnings
- 8/6/25 - Beat
IMNM
Sec Filings
- 12/30/25 - Form 4
- 12/23/25 - Form 4
- 12/22/25 - Form SCHEDULE
- IMNM's page on the SEC website